Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

    Supports laboratory optimization and clinical validation of cancer biomarkers and assays using human samples to address defined clinical needs; clinical trials are not allowed.

    Browse similar grants
    Cancer Research Grants 2026
    OverviewSimilar Grants
    OverviewSimilar Grants

    Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

    NCI supports research on how biospecimen collection, processing, and storage affect biomarkers, aiming to standardize handling and improve clinical assay development; clinical trials are not allowed.

    HHS-NIH11Due Feb 4, 2027$1,250,000

    NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)

    NIH supports investigator-initiated observational or biomarker validation studies requiring prospective collection or continued analysis of data or biospecimens; clinical trials are not allowed.

    HHS-NIH11Due Feb 5, 2027$2,500,000

    Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

    This grant funds projects to further develop and validate innovative technologies that advance cancer research or clinical care, focusing on technical improvements and rigorous validation for broad adoption.

    HHS-NIH11Forecasted Jun 4, 2027$300,000Forecasted

    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

    This grant supports investigator-initiated clinical trials to reduce cancer burden through early detection, prevention, and survivorship improvements.

    HHS-NIH11Due Jan 7, 2027

    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

    This grant funds early-stage, highly innovative technology development projects to improve cancer research or clinical care, focusing on proof-of-concept studies with high potential impact in cancer-related fields.

    HHS-NIH11Forecasted Jun 4, 2027$150,000Forecasted